{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:27:40Z","timestamp":1783024060248,"version":"3.54.6"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    A 67-year-old woman with coexisting papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC) harbored an ALK rearrangement on FISH. Despite surgery and 2 courses of\n                    <jats:sup>131<\/jats:sup>\n                    I treatments,\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT showed an intensely avid right lower-neck mass extending into the superior mediastinum. The patient was considered radioiodine-refractory (RAIR) and started ensartinib (225\u00a0mg once daily). CT at 3 months showed marked regression, with sustained disease control at 12 months. This case illustrates an objective imaging response to ALK-directed therapy in RAIR thyroid carcinoma.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006437","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:00:30Z","timestamp":1779120030000},"page":"e631-e632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Imaging Response to Ensartinib in Concurrent Papillary and Anaplastic Thyroid Carcinoma With ALK Rearrangement"],"prefix":"10.1097","volume":"51","author":[{"given":"Jinbo","family":"Gui","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7573-5106","authenticated-orcid":false,"given":"Wei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Hubei Key Laboratory of Molecular Imaging, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology"},{"name":"Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Wuhan, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"R1-20260702","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1530\/ERC-19-0325","article-title":"Characterization of thyroid cancer driven by known and novel ALK fusions","volume":"26","author":"Panebianco","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"R2-20260702","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"R3-20260702","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.3390\/jcm14092898","article-title":"Mutational landmarks in anaplastic thyroid cancer: a perspective of a new treatment strategy","volume":"14","author":"Pakkianathan","year":"2025","journal-title":"J Clin Med"},{"key":"R4-20260702","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"R5-20260702","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid Cancer","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"R6-20260702","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ecl.2018.10.010","article-title":"Diagnosis and management of anaplastic thyroid cancer","volume":"48","author":"Chintakuntlawar","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R7-20260702","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1089\/thy.2022.0389","article-title":"Case report of CCDC149-ALK fusion: a novel genetic alteration and a clinically relevant target in metastatic papillary thyroid carcinoma","volume":"32","author":"Lee","year":"2022","journal-title":"Thyroid"},{"key":"R8-20260702","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.3390\/cancers13143443","article-title":"Translational utility of liquid biopsies in thyroid cancer management","volume":"13","author":"Wijewardene","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R9-20260702","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s44276-024-00055-9","article-title":"Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings","volume":"2","author":"Kumar","year":"2024","journal-title":"BJC Rep"},{"key":"R10-20260702","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1111\/cas.13763","article-title":"Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer","volume":"109","author":"Sato","year":"2018","journal-title":"Cancer Sci"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:10:13Z","timestamp":1783023013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006437","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"2025-08-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}